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Highlights
• Mathematical model to analyse the optimal vaccination age against
Dengue in Brazil.
• Use epidemiological data from Brazil.
• Consider both hospitalisation and lethality risks.
• Model possible Dengue Antibody Enhancement.
• Calculations repeated with third and fourth infections asymptomatic.
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Abstract
In this paper we study a mathematical model to analyse the optimal vaccination
age against Dengue in Brazil. Data from Brazil are used to estimate the basic
reproduction numbers for each of the four Dengue serotypes and then the optimal
vaccination age is calculated using a method due to Hethcote [1]. The vaccine has
different efficacies against each serotype. Vaccination that is too early is ineffective
as individuals are protected by maternal antibodies but leaving vaccination until
later may allow the disease to spread.
First of all the optimal vaccination ages are calculated where there is just
one serotype in circulation and then when there are multiple serotypes. The cal-
culations are done using data both assuming constant vaccine efficacy and age-
dependent vaccine efficacy against a given serotype. The multiple serotype calcu-
lations are repeated assuming that the first infection is a risky infection and that
it is not (to model Dengue Antibody Enhancement). The calculations are then re-
peated when any third or fourth Dengue infections are asymptomatic, so that two
Dengue infections with different serotypes provide effective permanent immunity.
The calculations are also repeated when the age-dependent risk function (fitted
to Brazilian data) is hospitalisation from Dengue and when it is mortality due to
Dengue. We find a wide variety of optimal vaccination ages depending on both
the serotypes in circulation and the assumptions of the model.
Keywords: Dengue, Vaccination, Optimal Vaccination Age, Age-Structured
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Model, Serotype, Risk Function, Mortality, Hospitalisation, Mathematical Model.
1. Literature Review
Dengue is recognised as one of the most important vector-borne diseases
of our time with over 2.5 billion people living in endemic areas and infection
numbers estimated as high as 390 million annually [2, 3]. Over the past two
decades there has been a noticeable increase in mathematical models describ-
ing Dengue transmission dynamics in order to achieve a better understanding
of the disease as well as to be able to assess the potential of control mea-
sures such as vector-control and vaccinations [4]. The derived transmission
models can be broadly categorised as ‘single-serotype’ models [5, 6, 7] and
‘multi-serotype’ models [8, 9, 10].
Single-serotype models are usually based on the Ross-MacDonald model,
which was derived for the transmission of Malaria by Ross and later ex-
tended by MacDonald in the 1950s. These types of models describe both the
human and the mosquito populations by separating them into susceptible,
infectious and recovered compartments for humans, and susceptible and in-
fectious compartments for mosquitoes. Some models extend the number of
compartments for one or both species by including a latency period [6, 7].
While different research questions have led to a multitude of models most are
fairly similar to the original Ross-MacDonald model [4]. However, depending
on which aspects of the transmission or which type of control measures the
researchers aim to investigate the details vary significantly. Considering, for
example, vector-control strategies or the effect of temperature on the number
of mosquitoes requires a more detailed representation of the vector popula-
tion than is necessary for models that focus on other issues. Multi-serotype
models on the other hand are often concerned with the interaction of the
four different Dengue serotypes. Many of these models are based on the as-
sumption of a very short timescale as well as a dense mosquito population
so that a direct transmission model can be considered [10].
Understanding the interaction of the four different serotypes is crucial
for the understanding of transmission dynamics and for the implementation
of control strategies. The World Health Organisation (WHO) has identified
the development and implementation of vaccines against Dengue as an im-
portant means to reduce the burden of Dengue in their global strategy for
Dengue prevention and control 2012-2020 [3]. Accordingly, many researchers
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use mathematical models to assess the impact a potential Dengue vaccine
may have, or to find a cost-effective vaccination strategy. Modelling the im-
pact of vaccination proves to be very challenging for several reasons. One of
the main difficulties is the coexistence of more than one Dengue serotypes in
endemic areas resulting in the possibility of consecutive, heterologous infec-
tions. While there is little dispute about lifelong immunity to the serotype
a person was initially infected with [11], there is less clarity on the inter-
action between different serotypes. Effects of interaction that have been
documented are the short-term cross-immunity after a primary infection [12]
even though the length of this protection is not clear [13], as well as more
severe symptoms in secondary infections, i.e. Dengue Hemorrhagic Fever or
Dengue Shock Syndrome (DHF or DSS), which give rise to the theory of
antibody-dependent enhancement (ADE) [14]. It is thought that after a
short phase of cross-immunity following an infection a secondary, heterol-
ogous infection has a higher virulence caused by antibodies specific to the
first serotype. These specific antibodies bind on to the very similar second
Dengue serotype allowing the virus entry into its target cells without first
inactivating it and are thus enhancing the virulence during a secondary in-
fection. Studies have indeed found that the sequence of serotypes plays an
important role in whether an individual develops DHF or DSS rather than the
mild symptoms of Dengue Fever and that usually two heterologous infections
lead to permanent protection against all serotypes [15, 16]. Based on these
observations many models that considered multi-serotype transmission dy-
namics assume complete immunity after two heterologous infections [17, 18].
Considering these complex interdependencies it is not surprising that there
are contradictory conclusions about the effects of vaccination. There is an
overall agreement about the potential of vaccines to reduce Dengue Fever
cases drastically [6, 17, 19], yet some results indicate that vaccination in the
presence of ADE could lead to an increase in the incidence of DHF or DSS
under certain conditions [17, 20, 21].
Now that vaccinations against Dengue are becoming a reality with Sanofi
Pasteur’s Dengvaxia being licensed after twenty years of development as the
first Dengue vaccination in the world, it is important to be able to employ
the vaccine to protect populations against Dengue Fever and its more severe
forms in the best way possible. Some recent vaccination models attempt
to do this by finding the most cost-effective strategy or a strategy that will
lead to the necessary herd immunity for eradication of the disease [10, 22,
23]. However, considering that ADE might lead to an increase in DHF and
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DSS cases there are a multitude of aspects that need to be considered when
introducing a vaccine against Dengue. The WHO recommends the use of
Dengvaxia only in highly endemic settings [24]. In very high transmission
settings it is recommended to vaccinate individuals aged 9 years, and in
high transmission settings individuals between 11 and 14 years on a routine
vaccine calendar at 0, 6 and 12 months [25]. However, since the licensure
of Dengvaxia there has been an increasing concern about its application
particularly in seronegative recipients with some models concluding that in
this group the vaccine increases the risk of hospitalisation due to vaccine
induced ADE [26, 27, 28]. In fact, Aguiar et al. [29] have shown that for the
risk of hospitalisation to be reduced significantly only seropositive individuals
should be targeted after immunological screening. They further question
whether the vaccine efficacy is mainly correlated with the serostatus rather
than with the age of the recipient as indicated in the Dengvaxia efficacy trials
[30, 31]. If vaccination of seronegative recipients does indeed lead to ADE and
efficacy depends on the serostatus this would mean that the recommendations
of the WHO and Sanofi Pasteur might need to be reconsidered as noted by
Halstead [26]. Vaccination strategies should therefore be chosen in such a way
that the overall risk due to infection is minimised for the entire population.
This issue has been addressed by Hethcote [1] for vaccination against Measles
by considering a modelling framework to find the optimal vaccination ages
that minimise the lifetime expected risk of Measles in a human population.
He defined the lifetime expected risk as E =
∫∞
0
R(a)P (a)da where P (a) is
the probability of getting infected at age a (in other words if ∆a is small and
positive the probability that an individual gets infected in the time interval
[a, a + ∆a] is P (a)∆a + o(∆a)). R(a) is the risk of infection at age a, i.e. a
function describing the harmfulness of an infection at age a. However, while
some of the theory Hethcote used can be applied to the case of Dengue, one
has to note that there are significant differences between the two diseases.
Measles is usually transmitted directly from person to person, while in the
case of Dengue mosquitoes such as the Aedes aegypti mosquito function as
vectors. The fact that Dengue is a vector-borne disease results in different
transmission dynamics and a basic reproduction number R0 which depends
not only on the host but also on the vector species. Since there is only one
serotype of Measles, considering Dengue will also require a different definition
of the lifetime expected risk due to the coexistence of several serotypes.
Therefore this paper aims to identify the optimal ages of vaccination for
Dengue when more than one serotype is present. While the transmission
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of the serotypes is considered to take place independently the risk function
R(a) is utilised to incorporate observations such as an increased risk of DHF
or DSS in certain infection sequences; making it possible to take some of the
interactions between the serotypes into account while considering a single-
serotype transmission model.
2. Transmission Model
In order to find the optimal age of vaccination against Dengue the first
step is to consider the transmission dynamics of a single Dengue serotype. As-
suming independent transmission dynamics regardless of how many serotypes
are present, this transmission model can then be used to find the lifetime
expected risk for a specific vaccination strategy similar to that derived for
Measles by Hethcote [1].
For the one-serotype Dengue transmission model the age density of the to-
tal human population is divided into ‘unaffected’, ‘infected’ and ‘recovered’
given at age a and time t by UH(a, t), IH(a, t), and RH(a, t) respectively.
Note that the category ‘unaffected’ includes individuals who are passively
immune due to maternal antibodies as well as individuals that are suscep-
tible. Similarly the category of ‘recovered’ comprises individuals that have
recovered from natural infection or have been successfully vaccinated. Fol-
lowing Hethcote [1] we will assume that a fraction C(a) of the ‘unaffected’
individuals at age a are susceptible and that C(a) corresponds to the frac-
tion of susceptible individuals at age a who seroconvert when exposed to the
disease or the vaccine. The remaining fraction 1 − C(a) of individuals of
age a are passively immune, i.e. 1−C(a) represents the fraction of a cohort
of individuals who were initially entirely protected by maternal antibodies
at birth who are still protected at age a. These proportions are estimated
from data on the decline of maternal antibodies for each of the four serotypes
given in van Panhuis et al. [32]. Therefore passive immunes and susceptibles
are given by (1− C(a))UH(a, t) and C(a)UH(a, t) respectively. Further an
infection with any Dengue serotype will lead to an average infectious period
1
γH
after which the individual will be immune to that specific serotype for the
remainder of their lifetime. The per capita death rate of all humans is taken
to be µH without any additional deaths due to Dengue based on a very low
proportion of Dengue cases leading to death [33]. It will be assumed that the
total number of humans NH remains constant over time.
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The mosquito population on the other hand will be divided into ‘suscep-
tibles’, ‘exposed’ and ‘infectious’ given at time t by SM(t), LM(t) and IM(t)
respectively. Exposed mosquitoes will become infectious after a latency pe-
riod τ and stay infectious for the rest of their life. Again we take the per
capita death rate to be µM for all mosquitoes without any additional deaths
caused by the virus.
Table 1: Description of model parameters
Parameter Significance
q total rate per unit time at which mosquitoes bite humans,
b probability per bite that an initially susceptible human
bitten by an infected mosquito becomes infected,
c probability per bite that an initially susceptible mosquito
biting an infected human becomes infected,
NH total number of humans,
µH natural per capita death rate of humans,
γH per capita recovery rate of humans,
NM total number of mosquitoes,
µM natural per capita death rate of mosquitoes,
τ incubation period in mosquitoes (the extrinsic incubation
period),
Ai (i = 1, 2, 3) vaccination age for each of the three vaccination stages,
Vi (i = 1, 2, 3) vaccinated proportion of the population for each vaccina-
tion age
As described in Table 1 we denote q to be the total rate per unit time
at which a mosquito bites humans, b to be the probability per bite that an
initially susceptible human bitten by an infected mosquito becomes infected
and c the probability per bite that an initially susceptible mosquito biting
an infected human becomes infected. Then the forces of infection are given
by
λ(t) = qb
IM (t)
NH
, for humans, and (1)
λM (t) = qc
1
NH
∫ ∞
0
IH(a, t)da for mosquitoes.
For maximum effectiveness it is recommended that Dengvaxia be given
in three separate doses each at least six months apart. Hence in the model
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we assume that we vaccinate fractions Vi of the human population at three
vaccination ages Ai (i = 1,2,3) so that the probability of becoming immune
due to vaccination at age Ai is ViC(Ai). Therefore vaccination will result in
the matching conditions
UH(Ai + 0, t) = (1− ViC(Ai))UH(Ai − 0, t),
where UH(Ai + 0, t) = lim
a→A+i
UH(Ai, t),
and UH(Ai − 0, t) = lim
a→A−i
UH(Ai, t),
for i = 1, 2, 3. The model parameters used to describe the transmission
dynamics and the vaccination strategy are explained in Table 1.
The transmission model for a single Dengue serotype is therefore
∂UH
∂a
+
∂UH
∂t
= −λ(t)C(a)UH(a, t)− µHUH(a, t),
∂IH
∂a
+
∂IH
∂t
= λ(t)C(a)UH(a, t)− (µH + γH)IH(a, t),
∂RH
∂a
+
∂RH
∂t
= γHIH(a, t)− µHRH(a, t),
∂NH
∂a
+
∂NH
∂t
= −µHNH(a, t),
NH(a, t) = UH(a, t) + IH(a, t) +RH(a, t),
(2)
dSM
dt
= −λM (t)SM (t)− µMSM (t) + µMNM ,
dLM
dt
= λM (t)SM (t)− e−µM τλM (t− τ)SM (t− τ)− µMLM (t),
dIM
dt
= e−µM τλM (t− τ)SM (t− τ)− µMIM (t),
NM (t) = SM (t) + LM (t) + IM (t),
(3)
with initial conditions
UH(a, 0) = UH,0(a), IH(a, t) = IH,0(a) for τ ∈ [−τ, 0], RH(a, 0) = RH,0(a),
UH(0, t) = µHNH , IH(0, t) = 0, RH(0, t) = 0,
for the human population, and initial conditions
SM (t) = SM,0 for τ ∈ [−τ, 0], LM (0) = LM,0, IM (0) = IM,0,
for the mosquito population.
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For the sake of simplicity we have assumed a constant death rate. This
is a common practice in epidemiological modelling [34]. However a more
accurate estimate would be obtained by either a step death function where
everyone lives up to a constant age and then dies or by using real demographic
estimates for the death rates. This is a topic for further study.
3. Steady-State Force of Infection λ
The next step to find optimal vaccination ages is to derive λ, the force
of infection for humans at the steady-state age distribution, from the trans-
mission dynamics. In order to do this we consider the fractions at age a
of unaffected, infected and recovered humans rather than the total number
(that is the fractions at age a relative to the total population at age a).
The fractions will be denoted by the corresponding lower case letters where
the subscript H is dropped for the human population. At the steady-state
the densities with respect to age of the fractions for unaffected and infected
satisfy:
du
da
= −λC(a)u(a),
di
da
= λC(a)u(a)− γHi(a),
(4)
with initial and matching conditions
u(0) = 1, u(Ai + 0, t) = (1− ViC(Ai))u(Ai − 0, t), for i = 1, 2, 3,
i(0) = 0,
respectively where again UH(Ai + 0, t) = lim
a→A+i
UH(Ai, t), for i = 1, 2, 3, and
similarly for UH(Ai − 0, t), while the recovered fraction satisfies r(a) = 1 −
u(a)− i(a). This system of ODEs can be solved to give
u(a) =

e−λ
∫ a
0 C(s)ds, 0 ≤ a ≤ A1,
(1− V1C(A1)) e−λ
∫ a
0 C(s)ds, A1 < a ≤ A2,
(1− V1C(A1)) (1− V2C(A2)) e−λ
∫ a
0 C(s)ds, A2 < a ≤ A3,
(1− V1C(A1)) (1− V2C(A2)) (1− V3C(A3)) e−λ
∫ a
0 C(s)ds, A3 < a <∞,
(5)
and
i(a) = e−γHa
∫ a
0
λC(s)u(s)eγHsds (6)
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so that the densities of the total numbers of unaffected and infectious are
respectively
UH(a) = µHNHe
−µHau(a),
IH(a) = µHNHe
−(µH+γH)a
∫ a
0
λC(s)u(s)eγHsds.
(7)
Note that the equilibrium fraction of infected humans is
1
NH
∫ ∞
0
IH(a)da =
1
µH + γH
∫ ∞
0
λC(a)u(a)µHe
−µHada. (8)
For the human population to reach a steady-state age distribution the mosquito
population also needs to be at its equilibrium, therefore the exposed and in-
fectious mosquitoes satisfy
LM + IM =
cq
µM
1
NH
∫ ∞
0
IH(a)da SM ,
=
cq
µM
1
NH
∫ ∞
0
IH(a)da (NM − (LM + IM )),
from dSM
dt
= 0. Hence solving for LM + IM gives
LM + IM =
cqm
∫∞
0 IH(a)da
µM + cq
1
NH
∫∞
0 IH(a)da
,
where m = NM
NH
the ratio of mosquitoes to humans. IM further satisfies
IM =
cq
µM
e−µM τ
1
NH
∫ ∞
0
IH(a)da SM ,
= e−µM τ (LM + IM )
from dIM
dt
= 0.
Using these results in the definition of λ(t) the steady-state force of in-
fection is given by
λ =
q2bcme−µM τ 1NH
∫∞
0 IH(a)da
µM + qc
1
NH
∫∞
0 IH(a)da
.
This expression can be written in terms of the basic reproduction number
R0 which MacDonald [35] found to be
R0 =
q2bcme−µM τ
(µH + γH)µM
, (9)
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so that using (8) for 1
NH
∫∞
0
IH(a)da the steady-state force of infection satis-
fies
1 =
R0
∫∞
0 C(a)u(a)µHe
−µHada
1 + qc(µH+γH)µM
∫∞
0 λC(a)u(a)µHe
−µHada
. (10)
4. Serotype-specific Reproduction Numbers
In order to find the steady-state force of infection for a given vaccina-
tion strategy using equation (10) for each of the four Dengue serotypes the
serotype-specific basic reproduction numbers Ri0 are required. We have found
estimates for these reproduction numbers from the initial exponential phase
of outbreaks following the approach of Massad et al. [36].
Massad et al. [36] found an expression for the estimate of R0 by lineari-
sation of the differential equations for the age-independent proportions of
infected humans and infectious mosquitoes at the beginning of an epidemic.
The expression for R0 in terms of λ where λ is the exponential growth rate
at the beginning of an outbreak is given by
R0 =
(λ+ µM ) (λ+ µH + γH)
(µH + γH)µM
. (11)
The parameter values µM = 2.50× 10−2 day−1, µH = 3.72× 10−5 day−1, and
γH = 0.14 day
−1 were chosen from the literature [37, 38]. λ can be found by
fitting the number of new cases from an outbreak to an exponential curve
for datasets of each serotype.
We used Dengue case numbers separated by serotype provided by the
Brazilian Ministry of Health (SINAN) to find the first twelve weeks of each
major outbreak in Brazil in the years from 2000 to 2014. We then found
the corresponding outbreak period in each of five regions (North, North-
east, South, Southeast and Centre-West) to obtain upper and lower bounds
for the growth rate λ and hence upper and lower bounds for the serotype-
specific basic reproduction numbers for each of the Dengue virus serotypes
(denoted DENv1–DENv4) and each outbreak. While there were four major
outbreaks during the surveyed period for DENv1–DENv3, DENv4 only re-
emerged in Brazil in 2010 [39] and is responsible for two major epidemics in
2012 and 2013. The mean of the basic reproduction numbers of the consid-
ered outbreaks are taken as the serotype-specific reproduction number, while
the lowest and highest values in the regions are considered upper and lower
11
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Table 2: Serotype-specific Basic Reproduction Numbers
Serotype R0 lower bound upper bound
DENv1 3.3939 1.1898 4.2732
DENv2 2.4726 1.3141 5.3608
DENv3 3.2421 1.3621 7.2837
DENv4 3.2066 1.6684 3.5919
bounds. The resulting serotype-specific reproduction numbers with upper
and lower bounds from the regions are given in Table 2.
Note that these results highly depend on which weeks are considered to
correspond to the initial phase of an outbreak. This cannot be determined
exactly and usually differs for each of the regions due to different climatic
conditions. However, the results seem to be in agreement with previous
estimations of basic reproduction numbers for Dengue [40, 41].
5. Lifetime Expected Risk E
Using the above transmission model with the given vaccination ages we
now want to find the lifetime expected risk E for an individual that is born
into the population in order to choose vaccination ages that will minimise
this risk. The risk will be the total risk from infection that an individual is
exposed to during their lifetime, i.e. the probability P (a) of getting infected
at any given age a, multiplied by the risk R(a) an infection at this age poses,
multiplied by the probability e−µHa of being alive at age a. This definition of
the lifetime expected risk differs from that used by Hethcote [1] which does
not include the survival probability and thus leads to overestimation. Het-
hcote’s definition of the lifetime risk was also used by Massad et al. [42] in
designing vaccination programs against Rubella, by Zanetta et al. [43] in de-
signing optimal vaccination ages for Measles and by Amaku, Coudeville and
Massad [44] in designing vaccination programs against Dengue [44]. While
in many countries Dengue is primarily considered a childhood disease it does
affect people of all ages [11]. In fact, as is the case with many diseases, the
risk associated with infection while fairly low for young adults and middle-
aged people significantly increases again at older ages. Also as we shall see
later when we are considering the risks such as hospitalisation, including the
survival probability can make a big difference. However, this increased risk
should not be overrated in comparison to the risk of Dengue at young ages
12
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
since few people live very long lives and it is therefore important to include
the survival probability when calculating the lifetime expected risk.
For a scenario where only one serotype exists we know from the transmis-
sion model that the risk of getting infected at age a is given by λC(a)u(a)
where λ is the steady-state force of infection found as described in the pre-
vious section. Therefore the lifetime expected risk from Dengue when only
one serotype, e.g. the serotype DENv1, is in circulation is:
E1 = λ1
∫ ∞
0
R1(a)C1(a)u1(a)e
−µHada. (12)
When considering more than one serotype with independent transmission
dynamics the lifetime expected risk becomes the sum of the risks of possible
infection successions. The independence of the transmission of each serotype
means that the probability of getting infected with serotype i at age a is
λiCi(a)ui(a) while the probability of not having been infected up to age a
corresponds to ui(a), the proportion of unaffected at age a, and hence the
probability of having been infected up to age a is 1−ui(a) for each serotype.
Therefore for two serotypes the probability Pij(a) of getting infected with
serotype i at age a after previously having been infected with serotype j is
given by
Pij(a) = λiCi(a)ui(a)(1− uj(a)),
while the probability Pij¯(a) of getting infected with serotype i at age a with-
out ever having been infected with serotype j is
Pij¯(a) = λiCi(a)ui(a)uj(a).
The risk functions Rij(a) and Rij¯(a) describe respectively the risk that an
infection with serotype i poses after having been and not having been infected
with serotype j before. We will denote the expected risk of getting infected
with serotype i at age a by
Elasti (a) = Rij(a)Pij(a) +Rij¯(a)Pij¯(a)
so that the lifetime expected risk for two coexistent Dengue serotypes, e.g.
serotypes 1 and 2, is
E12 =
∫ ∞
0
[
Elast1 (a) + E
last
2 (a)
]
e−µHada. (13)
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Similarly for three serotypes the probabilities of getting infected with
serotype i at age a after previous infections with serotypes j and k, previous
infection with serotype j only, or no previous infection are given by
Pijk(a) = λiCi(a)ui(a)(1− uj(a))(1− uk(a)),
Pijk¯(a) = λiCi(a)ui(a)(1− uj(a))uk(a), and
Pij¯k¯(a) = λiCi(a)ui(a)uj(a)uk(a)
respectively. The corresponding risk functions are denoted byRijk(a), Rijk¯(a),
Rij¯k¯(a) respectively and the expected risk from getting infected with serotype
i at age a by
Elasti (a) = Rijk(a)Pijk(a) +Rijk¯(a)Pijk¯(a) +Rij¯k(a)Pij¯k(a) +Rij¯k¯(a)Pij¯k¯(a).
The lifetime expected risk for three Dengue serotypes, e.g. serotypes 1, 2
and 3, is then
E123 =
∫ ∞
0
[
Elast1 (a) + E
last
2 (a) + E
last
3 (a)
]
e−µHada. (14)
Note that for Pijk(a) and the associated risk Rijk(a) the order of the previous
infections with serotypes j and k is not relevant. This is the case because
independently of the order of previous infections an individual with this his-
tory is expected to have antibodies against both serotypes j and k for the
remainder of their life.
For four Dengue serotypes the probabilities of infection with serotype i
after three heterologous previous infections, two heterologous previous in-
fections, one heterologous previous infection, or no previous infection are
analogously given respectively by
Pijkl(a) = λiCi(a)ui(a)(1− uj(a))(1− uk(a))(1− ul(a)),
Pijkl¯(a) = λiCi(a)ui(a)(1− uj(a))(1− uk(a))ul(a),
Pijk¯l¯(a) = λiCi(a)ui(a)(1− uj(a))uk(a)ul(a), and
Pij¯k¯l¯(a) = λiCi(a)ui(a)uj(a)uk(a)ul(a)
with corresponding associated risk functions Rijkl(a), Rijkl¯(a), Rijk¯l¯(a) and
Rij¯k¯l¯(a). The expected risk from infection with serotype i at age a in this
case is defined as
Elasti (a) = Rijkl(a)Pijkl(a) +Rijkl¯(a)Pijkl¯(a) +Rijlk¯(a)Pijlk¯(a) +Riklj¯(a)Piklj¯(a)
+Rijk¯l¯(a)Pijk¯l¯(a) +Rikj¯l¯(a)Pikj¯l¯(a) +Rilj¯k¯(a)Pilj¯k¯(a) +Rij¯k¯l¯(a)Pij¯k¯l¯(a)
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so that the expected lifetime risk when all four Dengue serotypes coexist is
given by
E1234 =
∫ ∞
0
[
Elast1 (a) + E
last
2 (a) + E
last
3 (a) + E
last
4 (a)
]
e−µHada. (15)
The associated risk functions R(a) are an important factor when minimis-
ing the lifetime expected risk and need to be chosen so that the adverse effects
due to infection at age a are measured. One possible choice is the probability
of hospitalisation due to infection for any given age, but also the probability
of severe symptoms, or the probability of death could be used. If infection is
considered to be equally serious at any age or the risk is simply considered to
be getting infected R(a) = 1 can be chosen. When several serotypes coexist
the risk functions can also be used to incorporate the fact that an infection
with any serotype is usually harmless if no heterologous infection was ac-
quired before, hence for two serotypes Rij¯(a) = 0 could be used if an infection
which does not lead to DHF or DSS is considered to be harmless. Similarly
the risk functions R(a) can be used to incorporate no symptomatic Dengue
infections after the second. If two heterologous infections are assumed to
result in no subsequent symptomatic Dengue infections Rijk(a) = 0 can be
used in the case of three serotypes and Rijkl(a) = Rijkl¯(a) = 0 in the case of
four serotypes.
6. Results
We now present optimal vaccination ages for Dengue obtained numerically
by evaluating the expressions for the lifetime expected risk introduced in
Section 5. In order to find this risk the steady-state force of infection λ
needs to be computed for each serotype separately since our model assumes
independent transmission dynamics irrespective of the number of serotypes
in circulation. While most of the parameters required for the calculations are
equal for all serotypes, the basic reproduction numbers are different. These
serotype-specific reproduction numbers were found from the initial phases of
major outbreaks in Brazil from 2000 to 2014 as discussed in Section 4. The
death rates µH and µM of humans and mosquitoes, as well as the recovery rate
γH for humans were already used to calculate the basic reproduction numbers
and are given in Section 4. The remaining model parameters m = 1.5 (the
number of vectors per host), τ = 7 days (the latency period in mosquitoes),
b = 0.6 and c = 1 (the transmission probabilities from mosquitoes to humans
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and vice versa), which are needed to find the biting rate q from eq. (9) and
hence λ, are taken from literature [37, 45]. b, c and τ are assumed to be equal
for all serotypes. m is taken as the middle value of the range given in [45].
Dengvaxia, currently the only available vaccine against Dengue, is li-
censed for individuals aged between 9 and 45 years and is being adminis-
tered in three doses with 6 months between each dose. Based on this strat-
egy we consider fractions Vi to be vaccinated at ages A1, A2 = A1 + 6 and
A3 = A1 + 12 months. However, we allow vaccination to start between the
ages of 0 and 900 months, i.e. immediately after birth up to the age of 75
years. This interval is chosen in order to determine whether the prevailing
guidelines make it possible to achieve minimal lifetime expected risk. The
fractions Vi are assumed to be equal for each dose but incorporate the ef-
ficacy of the vaccine. Dengvaxia is a tetravalent vaccine and thus aims to
protect against all four serotypes. However, in two separate phase three tri-
als [30, 31] the vaccine efficacy was not only found to be dependent on the
serotype, but these serotype-specific efficacies were also found to be different
for the age-groups of participants under 9 years and 9 years or older. The ef-
ficacies obtained from the pooled data as presented by Hadinegoro et al. [30]
are summarised in Table 3. The vaccinated fractions Vi for each serotype are
then calculated using the relation Vi = 1− (1−eff ) 13 where eff is the vaccine
efficacy for that serotype as given in Table 3. When considering the change
in efficacy based on the age-groups the fraction vaccinated at each dose will
depend on the age at which the dose is administered, i.e. V1 = V2 6= V3
if A1 ∈ [8, 8.5) years and V1 6= V2 = V3 if A1 ∈ [8.5, 9) years. The re-
sults we present below will consider both constant efficacies and efficacies by
age-groups as in Table 3.
Table 3: Vaccine Efficacies as found by Hadinegoro et al. [30]
Serotype age-independent
eff
under 9 years
eff
9 years or older
eff
DENv1 54.7% 46.6% 58.4%
DENv2 43.0% 33.6% 47.1%
DENv3 71.6% 62.1% 73.6%
DENv4 76.9% 51.7% 83.2%
The optimal vaccination strategy will highly depend on what is considered
to be the risk of Dengue. An infection with Dengue can progress without
noticeable symptoms or, as mentioned before, severe symptoms leading to
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DHF, DSS, and even to death can be observed. Hethcote [1] noted in his
paper on Measles vaccination that setting R(a) = 1 describes a scenario
where getting infected by itself is already considered undesirable. For the
case of Dengue this choice is not particularly reasonable since many cases are
asymptomatic [46] and thus do not pose a significant threat to the infected
individual. We will therefore examine how the optimal vaccination ages are
influenced when the risk of an infection is taken to be the probability of
being hospitalised due to the severity of the symptoms, or of dying due to
an infection. Note that there is some degree of correlation between these
two risk measures since most Dengue cases leading to death are treated in
hospital prior to death.
There are several other factors worth considering when it comes to calcu-
lating the lifetime expected risk. In most endemic areas there are several of
the serotypes co-circulating and while infection with a given serotype leads
to lifelong immunity it is possible for individuals to be infected with any of
the other serotypes after a short period of cross-immunity. Many scientists
think that these secondary infections are indeed more dangerous than an
initial infection [14] and some argue that there is enough evidence that third
and fourth infections do not lead to symptomatic cases [15, 16]. We want to
explore the optimal vaccination ages when the actual transmission dynam-
ics agree with these theories. For both of the chosen risk-measures we will
therefore find the optimal vaccination ages for the case of risk-free primary
infections, no subsequent symptomatic Dengue infection after a secondary
infection and the combination of both of these, i.e. the only risky infection
is considered to be the secondary one. The results are presented in the next
two subsections first for hospitalisation and subsequently for lethality. In
these subsections all cases that require vaccination outwith the range of 9-45
years for which Dengvaxia is licensed to minimise the lifetime expected risk
are re-examined to compare with the minimum lifetime expected risk that
can be achieved by vaccinating in this age-range.
6.1. Hospitalisation
To begin with we consider the risk of Dengue to be the probability of
hospitalisation. Burattini et al. [47] used data provided by SINAN to eval-
uate the cases of hospitalisation by age. We used their data to find the risk
function R(a) describing the undesirability of Dengue in terms of hospitalisa-
tion by fitting a piecewise function and assuming the risk to remain constant
for ages above the highest age of the recorded data. The hospitalisation
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percentage is clearly highest at young (0-20 years) and old ages (>70 years)
with much lower values inbetween. In fact, the risk increases exponentially
for adults. We therefore determined the piecewise risk function to be of the
form:
R(a) =

0.09201ae−0.1828a, 0 ≤ a < 20,
0.02440e0.02356a, 20 ≤ a < 100,
0.02440e0.02356·100, 100 ≤ a <∞,
for risk of hospitalisation.
(16)
Table 4 summarises the optimal vaccination age A1 in months along with
the obtained minimal lifetime expected risk E for vaccination aiming at the
reduction of the risk of hospitalisation due to Dengue. The scenarios consid-
ered for each specific combination of serotypes are constant efficacy and effi-
cacy based on whether a dose is given before or after the age of 9 years, risky
and risk-free primary infections for combinations of at least two serotypes,
and asymptomatic tertiary and quaternary infections for combinations of
three or four serotypes. Below we discuss the findings presented in Table 4
in detail. Note that while the simulations were carried out for vaccination
ages between 0 and 900 months the results presented cover ages between 0
and 300 months for combinations with several coexisting serotypes since the
optimal vaccination ages are all fairly low and the behaviour at older vacci-
nation ages is similar to the one that can be observed for a single serotype
in existence as presented in Figure 1.
Even though in most endemic areas there are several Dengue serotypes
present we first investigate the optimal vaccination ages for each of the
serotypes individually. The consequences of the vaccine efficacy and the
basic reproduction number are of particular interest in this case. Figure 1
shows the lifetime expected risk as a function of the age at which the first
dose of vaccine is administered for each of the serotypes. Figure 1a corre-
sponds to unchanged vaccine efficacies and Figure 1b to vaccine efficacies by
age-groups as given in Table 3.
Assuming that the efficacy is the same at any age we can observe from
Figure 1a that the lifetime expected risk for all four serotypes reaches its min-
imum for relatively young vaccination ages, i.e. it is first reached if the initial
vaccination dose is given between 9 and 22 months. However, for DENv1
and 2 the lifetime expected risk increases immediately after the optimum is
reached, which is not the case for DENv3 and 4. For these two serotypes the
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(a) The optimal vaccination age A1 is 22, 9, 12-31
and 13-106 months for DENv1, 2, 3 and 4 respec-
tively.
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(b) The optimal vaccination age A1 is 109, 109,
108 and 108-176 months for DENv1, 2, 3 and 4
respectively.
Figure 1: The lifetime expected risk E for endemic areas with a single serotype in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The risk function is given by equation (16).
lifetime expected risk can be reduced to zero if the first dose of vaccination is
given at any age between 12 and 31 months, and 13 and 106 months respec-
tively. Further Figure 1a shows that the lifetime expected risk obtained for
DENv2 stands out since the curve is much flatter than those for the other
serotypes and as a result the lifetime expected risk of getting hospitalised
due to an infection with serotype 2 is the highest for all serotypes at young
vaccination ages but the lowest if vaccination is initiated later on. These
observations can be explained by looking at Tables 2 and 3 to compare re-
spectively the basic reproduction numbers and vaccine efficacies for the four
serotypes. The efficacy is lowest for DENv2, followed by DENv1 and with
quite significantly higher values by DENv3 and 4, on the other hand the basic
reproduction number is by far the lowest for DENv2 with a value of approx-
imately 2.5, while DENv3 and 4 have similar basic reproduction numbers of
roughly 3.2 and DENv1 has the highest at almost 3.4. Vaccination leads to
a reduction in cases of natural infections the extent of which depends on the
effectiveness of the vaccine and the age at which it is administered. If, for ex-
ample, vaccination is first given late in life the reduction in natural infections
may not be significant even if the efficacy was 100% since most people will
have already had the infection by the time they get vaccinated, this can be
observed in Figure 1a since for all serotypes the lifetime expected risk is very
flat at ages above 750 months (62.5 years) independently of the effectiveness
of the vaccine. The number of natural infections for each of the serotypes is
correlated with the basic reproduction number, therefore what can be seen
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from Figure 1a is that while the number of infections for DENv2 is lower
due to the lower basic reproduction number the efficacy for this serotype
is fairly low as well and therefore the number of infections is only slightly
reduced even if the vaccination is started at young ages leading to a compa-
rably flat lifetime expected risk. Similarly the higher efficacy for serotypes 3
and 4 leads to a reduction in cases of these infections which for vaccination
at young ages is so significant that the risk of hospitalisation can be reduced
to zero. On the other hand at older ages after many natural infections have
already occurred the higher efficacy does not reduce the number of infections
significantly so that at these ages the lifetime expected risk is higher than for
DENv2. For serotype 1 the fairly low efficacy but high basic reproduction
number means that only vaccination that takes place very early to prevent
many infections can reduce the lifetime expected risk below that of DENv2.
For constant efficacy the optimal vaccination ages are all below 9 years
of age which under the current license for Dengvaxia cannot be satisfied, we
therefore restrict the possible vaccination strategies to be initiated between
108 and 539 months so that all three vaccination doses are administered be-
fore an individual reaches age 46 years. Figure 1a indicates that under these
restrictions the optimal vaccination ages for all four serotypes should be 9
years, i.e. 108 months, the exact results from the simulations, owing to the
flat objective function and the use of (possibly inaccurate) numerical inte-
gration, are 109 months for DENv1, 3 and 4 and 108 months for DENv2.
The minimum lifetime expected risk under the age-constraint of the license
is significantly higher for all four serotypes, with an increase compared to the
values found for optimal vaccination ages of approximately 47% and 24% for
DENv1 and 2, the risk for DENv3 and 4 can be entirely eliminated if vac-
cination starts at 12 and 13 months, while it is 1.05× 10−2 and 4.19× 10−4
respectively if the license restrictions are considered. Table 6 on page 38
summarises the comparison of the lifetime expected risk achieved at optimal
vaccination age to that achieved under the license restrictions for all scenarios
where it differs.
If instead we consider the vaccine efficacy to depend on whether a dose is
given before or after 9 years of age Figure 1b has several interesting features
while the main observations of the case for constant efficacy are transferable.
When none of the vaccination doses is given to children 9 years or older (i.e.
A1 < 96 months) the lifetime expected risk is higher than found for constant
efficacy with the same vaccination ages since the overall efficacy is lower for
all serotypes as can be seen from Table 3. Once the age of the first dose
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increases to 96 months the third dose has the efficacy given in Table 3 for
children aged 9 or older and the lifetime expected risk drops since the efficacy
of the third dose is now much higher, i.e. significantly more infections will
be prevented with the final dose if it is administered to children of at least 9
years. The same happens again once the second dose is administered at age 9
or above and one last time when all three vaccination doses are administered
in this age-group. These three drops are obvious in Figure 1b. For A1 ≥ 108
months only the efficacy of the second age-group is relevant and it can be
observed that the efficacy for DENv4 is is in fact so high in this age group that
the lifetime expected risk of an infection with DENv4 is zero if vaccination is
initiated between the ages of 108 and 154 months. The optimal vaccination
ages are 109 months for DENv1 and 2 and 108 months for DENv3, again we
believe that due to the numerical integration the simulation results can be
understood in such a way that the minimal lifetime expected risk in all these
cases is achieved once the efficacy for all three doses is that for 9 and older.
In summary in an endemic area with only a single serotype in circulation
the ages for which Dengvaxia is currently licensed (9-45 years) would be
much too high if vaccine efficacy is age-independent, whereas if the efficacy
does change at 9 years of age the optimal vaccination ages we found match
the licensed ages. Note that while the optimal ages for constant vaccine
efficacy lie outside the licensed ages the age-dependent efficacy cases are
more realistic and all optimal vaccination ages relating to this are within the
permitted range.
Now we will examine the much more realistic cases of several coexisting
serotypes in an endemic region. We want to find the optimal vaccination
ages for all possible combinations of co-circulating serotypes and investigate
how strongly the age depends on whether a primary infection is considered
dangerous or not. We in fact expect the optimal vaccination age to be sig-
nificantly impacted by this since in the case where no risk is attached to a
primary infection vaccination will only be beneficial if an individual is likely
to get at least two heterologous infections during their lifetime. Results for
two, three and all four co-circulating serotypes are shown in Figures 2 to 4
respectively. As before the vaccine efficacy for Figures 2a, 3a and 4a is as-
sumed to be age-independent and for Figures 2b, 3b and 4b the efficacy is
based on age-groups of younger than 9 and 9 or older. In both cases the
graph at the top shows results when all infections are equally risky, while
the bottom graph corresponds to a primary infection being free of risk since
an initial infection with any serotype does not lead to significant symptoms.
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For the bottom plots the risk functions for a primary infection are therefore
taken to be Rij¯(a) = 0, Rij¯k¯(a) = 0 and Rij¯k¯l¯(a) = 0 respectively.
To begin with let us consider an endemic area where two serotypes are
present. From Table 4 we can see that the optimal vaccination age A1 de-
pends on the risk associated with a primary infection whether efficacy is based
on age-groups or not. When the efficacy is constant and all infections have
the same risk the optimal ages range from 12 months for the co-circulation of
DENv2 and 3 to 22 months for DENv1 and 3, while the risk for DENv3 and
4 is in fact zero for A1 between 13 and 31 months, i.e. for the ages at which
both the risks for DENv3 and DENv4 were found to be eradicated. On the
other hand, if a primary infection is risk-free the ages for all combinations
of two serotypes apart from DENv3 and 4 significantly increase and range
from 31 months for DENv1 and 3 (and DENv2 and DENv3) to 122 months
for DENv1 and 2. For these serotype-combinations the combined efficacy
is fairly low so that while the average age is increased due to vaccination
not enough infections are prevented and the lifetime expected risk is higher
if vaccines are administered too early. The reason for the optimal age be-
ing unchanged for DENv3 and 4 lies with the high efficacy for both these
serotypes since the number of prevented primary infections and secondary
infections is so significant that the risk can be eliminated.
This is no longer the case if efficacy is assumed age-dependent both for
risky and risk-free primary infections because the combined efficacy is lower
in this case until all doses are given to children aged at least 9 years and there-
fore too many natural infections to eliminate the risk already occur before
the higher efficacy is achieved. The optimal vaccination age in these cases is
therefore 108 months. For risky primary infections the remaining serotype
combinations require vaccination at 109 months, while for risk-free ones the
combinations of DENv1 and 4 and DENv2 and 4 have optimal vaccination
ages 174 and 175 months respectively. In any case the lifetime expected risk
is lower if a primary infection is considered risk-free since only subsequent
infections contribute to the risk. As was the case for a single serotype age-
dependent efficacy results in optimal vaccination ages of approximately 9
years for every scenario, for constant efficacy the optimal vaccination ages
under the restrictions of the current license are 109 months for all combina-
tions apart from DENv1 and 2 when primary infections are risk-free which
leads to minimal lifetime expected risk at 122 months as before as shown
in Table 6. The lifetime expected risk increases up to 93% compared to
the values found for low vaccination ages in all cases where elimination of
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the risk was not possible, for the combination of DENv3 and 4 it increases
from zero to 1.09× 10−3 for risky primary infections and to 5.05× 10−3 for
risk-free ones. Note that these results indicate that the specific combination
of serotypes in an endemic region needs to be considered before vaccination
programmes can be chosen adequately independently of whether efficacy is
age-dependent or not, particularly when primary infections are risk-free.
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(a) Top: The optimal vaccination age A1 is 16, 22,
22, 12, 13 and 13-31 months for DENv12, DENv13,
DENv14, DENv23, DENv24 and DENv34 respec-
tively. Bottom: The optimal vaccination age A1
is 122, 31, 105, 31, 106 and 13-31 months for
DENv12, DENv13, DENv14, DENv23, DENv24
and DENv34 respectively.
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(b) Top: The optimal vaccination age A1 is
109 months for combinations DENv12, DENv13,
DENv14, DENv23 and DENv24, and 108 months
for DENv34 respectively. Bottom: The optimal
vaccination age A1 is 109, 109, 174, 109, 175
and 108 months for DENv12, DENv13, DENv14,
DENv23, DENv24 and DENv34 respectively.
Figure 2: The lifetime expected risk E for endemic areas with two serotypes in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at the top show results for each
infection having the risk function given by equation (16), while the ones at the bottom assume R(a) = 0
for a primary infection. DENvij denotes the co-circulation of serotypes i and j.
For three and four serotypes co-circulating the results are fairly similar
to those of two serotypes as can be seen from Figures 3 and 4. For constant
efficacy the optimal vaccination ages increase for risk-free primary infections.
The only scenario where the age is unchanged is the co-circulation of DENv2,
3 and 4 due to the combination of high efficacies for DENv3 and 4 and low
basic reproduction number of DENv2. For risky primary infections the age
ranges from 13 to 22 months, while for risk-free ones the age ranges from
13 to 106 months if efficacy is constant. For efficacy based on the age-
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(a) Top: The optimal vaccination age A1 is 16,
16, 22 and 13 months for DENv123, DENv124,
DENv134 and DENv234 respectively. Bottom:
The optimal vaccination age A1 is 31, 106, 31 and
13 months for DENv123, DENv124, DENv134 and
DENv234 respectively.
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(b) Top: The optimal vaccination age A1 is 109
months for all combinations DENv123, DENv124,
DENv134 and DENv234 respectively. Bottom:
The optimal vaccination age A1 is 109 for
DENv123, DENv124 and DENv234 respectively,
and 173 months for DENv134.
Figure 3: The lifetime expected risk E for endemic areas with three serotypes in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at the top show results for each
infection having the risk function given by equation (16), while the ones at the bottom assume R(a) = 0
for a primary infection. DENvijk denotes the co-circulation of serotypes i, j and k.
groups risky primary infections all lead to optimal vaccination age of 109
months and risk-free ones to ages between 109 and 173 months and the
drops caused by the increased efficacy are again obvious. It is noteworthy
that near-optimal vaccination can be achieved for a much larger age-range if
a primary infection is considered free of risk and efficacy is constant when all
four serotypes are present. The same is true for certain combinations of fewer
serotypes such as DENv1, 3 and 4 or DENv1 and 2. If efficacy is based on
age groups near-optimal lifetime expected risk is indeed achieved for wider
age-ranges in almost every case. The increase in optimal age for risk-free
primary infections is because vaccination is only sensible if individuals are
infected at least twice, so that vaccination is ideal if it reduces the number of
secondary infections. It can also be seen from these results that the current
ages for which Dengvaxia is licensed are much too high to achieve minimal
lifetime expected risk unless efficacy depends on the age at which each dose
is given. By limiting the possible vaccination ages to conform to the current
license again the vaccination should take place at approximately 9 years of
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age, i.e. in all cases the age increases to 109 months with lifetime expected
risk increases varying significantly as presented in Table 6, e.g by less than
1% for DENv1, 2 and 4 with risk-free primary infections but up to 95% for
the combination of serotypes 1, 3 and 4 when primary infections are risky.
0 100 200 300
0.00
0.05
0.10
0.15
0.20
A1 in months
E
D1234
0 100 200 300
0.00
0.02
0.04
0.06
0.08
0.10
A1 in months
E
(a) Top: The optimal vaccination age A1 is 16
months. Bottom: The optimal vaccination age A1
is 31 months.
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(b) Top: The optimal vaccination age A1 is 109
months. Bottom: The optimal vaccination age A1
is 109 months.
Figure 4: The lifetime expected risk E for endemic areas with all four serotypes in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at the top show results for each
infection having the risk function given by equation (16), while the ones at the bottom assume R(a) = 0
for a primary infection.
Many models so far assume complete immunity after two infections with
heterologous serotypes [17, 18] based on studies reporting that third and
fourth infections do not cause clinical disease [15, 16, 48]. We will therefore
investigate how the optimal vaccination ages for three and four coexisting
serotypes change. This will change the risk function for getting infected which
is used to calculate E for third and fourth infections such that Rijk(a) = 0
for three and Rijkl¯(a) = 0 and Rijkl(a) = 0 for four co-circulating serotypes.
Asymptomatic third and fourth infections will certainly lead to a lower life-
time expected risk since only primary and secondary infections contribute to
it. Note that asymptomatic third and fourth infections implies that vaccina-
tion after a secondary infection will no longer have any effect. Our results
are shown in Figure 5. We can immediately see that the lifetime expected
risk is indeed lower if third and fourth infections are asymptomatic and that
26
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T0 100 200 3000.00
0.05
0.10
0.15
A1 in months
E
D123 D124 D134 D234
0 100 200 300
0.00
0.01
0.02
0.03
0.04
A1 in months
E
(a) Top: The optimal vaccination age A1 is 16
months for DENv123, and 22 months for DENv124,
DENv134 and DENv234 respectively. Bottom:
The optimal vaccination age A1 is 122, 122, 33 and
32 months for DENv123, DENv124, DENv134 and
DENv234 respectively.
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(b) Top: The optimal vaccination age A1 is 109
months for all combinations DENv123, DENv124,
DENv134 and DENv234 respectively. Bottom:
The optimal vaccination age A1 is 109 months for
DENv123, DENv134 and DENv234 respectively,
and 166 months for DENv124.
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(c) Top: The optimal vaccination age A1 is 16
months. Bottom: The optimal vaccination age A1
is 73 months.
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(d) Top: The optimal vaccination age A1 is 109
months. Bottom: The optimal vaccination age A1
is 109 months.
Figure 5: The lifetime expected risk E for endemic areas with three or four serotypes in circulation given
as a function of vaccination age A1 in months which corresponds to the age at which the first of three
doses is given. It is assumed that secondary infections lead to no subsequent symptomatic infections for
all other serotypes so that Rijk(a) = 0 for third and Rijkl(a) = 0 and Rijkl¯(a) = 0 for fourth infections.
(a) and (c) show the risk for constant vaccine efficacies for three and four serotypes, while (b) and (d)
show vaccine efficacies depending on the age groups <9 years and ≥ 9 years as shown in Table 3. The
graphs at the top show results for each primary and secondary infection having the risk function given by
equation (16). The ones at the bottom assume Ri(a) = 0 for a primary infection.
27
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
there is fairly little change in optimal vaccination ages in comparison to
the previous results independently of the number of serotypes circulating or
whether efficacy is constant or based on age-groups. The only exceptions to
this are DENv1, 2, 3 and all serotypes coexisting if efficacy is constant and
primary infections are risk-free. In these two cases the assumption of asymp-
tomatic third and fourth infections leads to an increased optimal vaccination
age. However, in both cases the lifetime expected risk is in fact near-optimal
for a significant age-range that includes similarly low ages as found for the
same combinations if third and fourth infections are symptomatic. For three
serotypes from Figure 5a we can see that if the vaccine efficacy is constant
and a primary infection is risky the optimal ages are still very low between 16
and 22 months, while for risk-free primary infections the optimal vaccination
ages range from 32 to 122 months. Similarly for four serotypes Figures 5c
and 5d show that the optimal vaccination ages are 16 and 73 months for
risky and risk-free primary infections for constant efficacy. The optimal age
if efficacy is age-dependent is 109 months for all four serotypes and for all
combinations of three serotypes apart from DENv1, 2 and 4 co-circulating
for risk-free primary infections which requires vaccination at 166 months.
Again we compare the achieved lifetime expected risk at the best age to
that achieved if the age is limited to the license. As was the case for symp-
tomatic tertiary and quaternary infections we only need to consider the case
of constant efficacy since all results for age-dependent efficacy already satisfy
the restriction, the results are similar albeit the percentage increase of the
lifetime expected risk is much higher in some cases as can be seen in Table 6.
6.2. Lethality
In this section we consider lethality as the risk of a Dengue infection,
i.e. the goal of vaccination is to reduce the probability of death due to
Dengue for the population. We found the risk function based on lethality
from unpublished data [49] similarly to that for hospitalisation in Section 6.1.
The risk of lethality is always significantly lower than that of hospitalisation
as expected. However, if considering lethality the risk for individuals at older
ages is significantly higher than for any other age-group including children
and teenagers which is not the case for hospitalisation. The risk of lethality
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is given by:
R(a) =

6.995× 10−4ae−0.2418a, 0 ≤ a < 20,
3.236× 10−5e0.06633a, 20 ≤ a < 100,
3.236× 10−5e0.06633·100, 100 ≤ a <∞,
for risk of death. (17)
Table 5 presents the optimal vaccination age A1 in months along with
the obtained minimal lifetime expected risk E for vaccination aiming at the
reduction of the risk of death due to Dengue. In this section we discuss the
findings presented in this table in detail in the same manner as for the risk
of hospitalisation.
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0.00
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1.00
×10−3
A1 in months
E
D1 D2 D3 D4
(a) The optimal vaccination age A1 is 557, 706,
12-31 and 13-106 months for DENv1, 2, 3 and 4
respectively.
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(b) The optimal vaccination age A1 is 544, 693,
108 and 108-176 months for DENv1, 2, 3 and 4
respectively.
Figure 6: The lifetime expected risk E for endemic areas with a single serotype in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The risk function is given by equation (17).
Again we start by finding optimal ages for the theoretical scenario of
a single Dengue serotype in circulation in order to compare the effect of a
constant or age-group based vaccine efficacy for each serotype and restrict the
vaccination ages to conform to the license if necessary to evaluate the impact
of the licensed age-range as presented in Table 6. The corresponding results
are shown in Figures 6a and 6b respectively. For the efficacy being equal at
all ages we can see that the lifetime expected risk due to death is eradicated
at the same ages as was the case for hospitalisation for DENv3 and 4 if there
is no age-restriction. The optimal vaccination ages for serotypes DENv1
and 2 on the other hand are much higher, i.e. 557 months for DENv1 and
706 months for DENv2 and even at these high vaccination ages the lifetime
expected risk of death due to serotypes 1 and 2 remains higher than that
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of death due to the other two serotypes for similar vaccination ages. This
is because of the low efficacy of the vaccine for DENv1 and 2 as well as the
high risk of death at older ages. Vaccination aims to decrease the number
of infections in the population but increases the average age of infection.
Therefore, the optimal vaccination age needs to be chosen so that the benefit
of fewer infections outweighs the higher risk if those infections that do occur
are at more dangerous ages. Since the efficacy of the vaccine for DENv1 and
2 is fairly low the number of cases will not be reduced as much as for the
other serotypes so that vaccination at older ages is more effective. On the
other hand the efficacy for DENv3 and 4 is large enough to stop the spread
of these serotypes if it is administered early enough. The optimal vaccination
ages for DENv1 and 2 are therefore above 45 years, while those for DENv3
and 4 are below 9 years. If the age-range of the license is applied the obtained
ages are 538, 539, 108 and 109 months for DENv1, 2, 3 and 4 respectively, i.e.
taking the limited precision of the simulations into account the vaccination
age can be taken to be 9 years if the optimal one is found to be below this
age and 539 months if it is is found to be above this age as can be seen from
Table 6. As shown in Figure 6a the percentage increase from the minimal
lifetime expected risk is significantly below 1% and approximately 1.6% for
DENv1 and DENv2 respectively with the age-restriction applied, for DENv3
and 4 not being able to vaccinate at early ages leads to lifetime expected risks
of 3.65× 10−4 and 1.73× 10−5 and therefore the license makes it impossible
to achieve eradication as is the case otherwise. For efficacy based on age-
groups the optimal vaccination age is A1 = 108 months for serotype 3 and
A1 = 108-176 months for serotype 4 similarly to the case of hospitalisation.
For serotypes 1 and 2 optimal results are achieved at age A1 = 544 and
693 months respectively which are still very high vaccine ages. The results of
restricting the ages to between 108 and 539 months again leads to vaccination
ages at the upper limit of the range with hardly any impact on the lifetime
expected risk achieved as shown in Table 6. The license restriction only makes
it possible to achieve good results for hospitalisation if efficacy is assumed
age-dependent. This is not the case for lethality since the achievable lifetime
expected risks are very close to the minimal ones for all serotypes when
efficacy is age-dependent, and for serotypes 1 and 2 if efficacy is constant.
However, if efficacy is assumed constant and DENv3 or 4 are considered to
circulate restricting the age leads to comparably bad results.
Now we want to find the optimal vaccination ages for several co-circulating
serotypes. Again we will consider how the assumption of a primary infection
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(a) Top: The optimal vaccination age A1 is
643, 31, 106, 22, 22 and 13-31 months for
DENv12, DENv13, DENv14, DENv23, DENv24
and DENv34 respectively. Bottom: The optimal
vaccination age A1 is 735, 31, 105, 12, 13 and 13-31
months for DENv12, DENv13, DENv14, DENv23,
DENv24 and DENv34 respectively.
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(b) Top: The optimal vaccination age A1 is
628, 109, 176, 109, 109 and 108 months for
DENv12, DENv13, DENv14, DENv23, DENv24
and DENv34 respectively. Bottom: The opti-
mal vaccination age A1 is 728, 616, 176, 706, 176
and 108 months for DENv12, DENv13, DENv14,
DENv23, DENv24 and DENv34 respectively.
Figure 7: The lifetime expected risk E for endemic areas with two serotypes in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at the top show results for each
infection having the risk function given by equation (17), while the ones at the bottom assume R(a) = 0
for a primary infection. DENvij denotes the co-circulation of serotypes i and j.
being risk-free affects the optimal ages. The results corresponding to risky
primary infections are shown at the top of Figures 7a to 9b and those for
risk-free ones at the bottom.
For two coexisting serotypes in an endemic area the optimal vaccination
ages very much depend on the serotypes present independently of whether
a primary infection is considered risky and whether efficacy is based on age-
groups or assumed constant. If serotypes 1 and 2 are coexisting the optimal
ages are very high with 643 and 735 months for risky and risk-free primary
infections respectively and constant efficacy, similar results are obtained for
age-dependent efficacy. For serotypes 1 and 4 coexisting the corresponding
ages are 106 and 105 months which is still fairly high and for age-based effi-
cacy the age is 176 months in both cases. All remaining combinations require
vaccination between 12 and 31 months if efficacy is constant and serotypes 3
and 4 can be eradicated if vaccination is started at any age between 13 and
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31 months. For age-dependent efficacy these serotype combinations lead to
optimal vaccination ages of 108 or 109 months if primary infections are risky
and ages between 108 and 706 months otherwise. Interestingly when the
results for risky and risk-free primary infections are compared a decrease in
optimal ages in some of the cases for constant efficacy can be observed, while
age-dependent efficacy leads to an increase in most cases with some ages
being unchanged. The results for serotype combinations excluding DENv2,
in comparison to those where DENv2 is present can clearly be distinguished
in Figures 7a and 7b since those including DENv2 tend to lead to a higher
lifetime expected risk due to the low efficacy of serotype 2. Many of the opti-
mal ages found for two serotypes are either below 9 years or above 45 years,
so that restricting the ages to the license result in increases from the mini-
mal lifetime expected risk between approximately 0.5 and 39%, apart from
serotypes 3 and 4 coexisting for which the risk could be eradicated at young
ages, but can now only be reduced to between 2.12× 10−4 and 3.82× 10−4
depending on whether efficacy is constant or age-dependent and whether pri-
mary infections are risky. The optimal vaccination ages are again the lowest
or highest possible in most cases, however, while for hospitalisation ages be-
low 9 years would increase to 9 years and ages above 45 years decrease to 45
years this is no longer the case here, e.g. DENv1 and 3 require vaccination
at 31 months for risky and risk-free primary infections and constant efficacy,
however limiting the age to between 9 and 45 years results in an optimal age
of 519 and 538 months.
We will now consider endemic areas where there are three of four serotypes
present. For combinations of three serotypes we can see from Figure 8 that
combinations including serotype 2 again lead to a higher lifetime expected
risk than that of DENv1, 3 and 4 due to the low efficacy for this serotype.
Further the optimal vaccination ages for risky primary infections are between
22 and 106 months for constant efficacy and between 109 and 575 months
for age-dependent efficacy. Most of these ages increase if primary infections
are considered risk-free to between 31 and 643 months for constant efficacy
and 108 and 636 months for age-dependent efficacy, with the combination
of DENv2, 3 and 4 being an exception if efficacy is constant where the op-
timal vaccination age is 13 months for risk-free primary infections. For all
four serotypes coexisting and a constant efficacy the the optimal vaccination
age is 31 months for both risky and risk-free primary infections. If efficacy
is age-dependent the corresponding optimal ages are 109 and 575 months
respectively, so that if primary infections are free of risk the optimal age sur-
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(a) Top: The optimal vaccination age A1 is 31,
106, 31 and 22 months for DENv123, DENv124,
DENv134 and DENv234 respectively. Bottom:
The optimal vaccination age A1 is 643, 636, 31 and
13 months for DENv123, DENv124, DENv134 and
DENv234 respectively.
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(b) Top: The optimal vaccination age A1 is
575, 176, 109 and 109 months for DENv123,
DENv124, DENv134 and DENv234 respectively.
Bottom: The optimal vaccination age A1 is 636,
616, 108 and 109 months for DENv123, DENv124,
DENv134 and DENv234 respectively.
Figure 8: The lifetime expected risk E for endemic areas with three serotypes in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at the top show results for each
infection having the risk function given by equation (17), while the ones at the bottom assume R(a) = 0
for a primary infection. DENvijk denotes the co-circulation of serotypes i, j and k.
passes the maximum guideline age. For three and four coexisting serotypes
and constant efficacy many optimal vaccination ages are below 9 years, while
the remaining ones are at least 46 years. Even if efficacy is based on age-
groups there are combinations where the optimal age is outwith the currently
licensed age-range of 9-45 years. Limiting the age-range to the license again
results in the expected shift of vaccination age to approximately 9 years in
most cases in which the optimal age was found below this value. An exception
to this is seen when the vaccine efficacy is constant for the combination of
DENv1, 2 and 3 if a primary infection is considered risky and if it is risk-free
for all four serotypes and DENv1, 3 and 4 co-circulating, in those cases the
optimal vaccination age increases from 31 to 538 or 539 months with the life-
time expected risk increasing between 6 and 37% as given in Table 6. In the
remaining cases the increase from the minimal lifetime expected risk ranges
from 22 to 49% for constant efficacy and from 0.2 to 1.3% for age-dependent
efficacy. Therefore it can again be said that if efficacy is age-dependent the
age-range for which Dengvaxia is licensed makes it possible to achieve near
34
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
optimal lifetime expected risk.
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(a) Top: The optimal vaccination age A1 is 31
months. Bottom: The optimal vaccination age A1
is 31 months.
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(b) Top: The optimal vaccination age A1 is 109
months. Bottom: The optimal vaccination age A1
is 575 months.
Figure 9: The lifetime expected risk E for endemic areas with all four serotypes in circulation given as a
function of vaccination age A1 in months which corresponds to the age at which the first of three doses is
given. (a) shows the risk for constant vaccine efficacies, while (b) shows vaccine efficacies depending on
the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at the top show results for each
infection having the risk function given by equation (17), while the ones at the bottom assume Ri(a) = 0
for a primary infection.
Lastly we want to incorporate no subsequent symptomatic infection af-
ter a secondary infection when the Dengue risk function is lethality. The
results for this are shown in Figure 10 for both three and four co-circulating
serotypes. These results are particularly interesting for the case of a risk-
free primary infection. By assuming asymptomatic third and fourth Dengue
infections and risk-free primary infections the lifetime expected risk is en-
tirely based on secondary infections so that these results may be considered
the most realistic if the risk is considered to be the risk of death. First we
consider constant efficacy, when for combinations where both DENv3 and
DENv4 are in existence the optimal vaccination ages are fairly low if primary
infections are risk-free, i.e. 31 months for three serotypes and 36 months for
four. These are the only combinations if tertiary and quaternary infections
are asymptomatic that lead to optimal vaccination ages outwith the range of
9-45 years and restricting the age to this range leads to vaccination ages of
109 months and an increase of approximately 20 to 30%. For combinations
of DENv1, 2 and 3 DENv1, 2 and 4 the optimal ages are 288 and 280 months
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(a) Top: The optimal vaccination age A1 is 288,
280, 31 and 31 months for DENv123, DENv124,
DENv134 and DENv234 respectively. Bottom:
The optimal vaccination age A1 is 428, 423,
334 and 423 months for DENv123, DENv124,
DENv134 and DENv234 respectively.
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(b) Top: The optimal vaccination age A1 is
278 months for DENv123 and 109 months for
DENv124, DENv134 and DENv234 respectively.
Bottom: The optimal vaccination age A1 is 417,
400, 319 and 400 months for DENv123, DENv124,
DENv134 and DENv234 respectively.
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(c) Top: The optimal vaccination age A1 is 36
months. Bottom: The optimal vaccination age A1
is 219 months.
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(d) Top: The optimal vaccination age A1 is 109
months. Bottom: The optimal vaccination age A1
is 215 months.
Figure 10: The lifetime expected risk E for endemic areas with three or four serotypes in circulation
given as a function of vaccination age A1 in months which corresponds to the age at which the first of
three doses is given. It is assumed that secondary infections lead to permanent cross-immunity for all
other serotypes so that Rijk(a) = 0 for three and Rijkl(a) = 0 and Rijkl¯(a) = 0 for fourth infections. (a)
and (c) show the risk for constant vaccine efficacies for three and four serotypes, while (b) and (d) show
vaccine efficacies depending on the age groups <9 years and ≥ 9 years as shown in Table 3. The graphs at
the top show results for each primary and secondary infection having the risk function given by equation
(17). The ones at the bottom assume Ri(a) = 0 for a primary infection.
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respectively for risky primary infections. The assumption of risk-free primary
infections leads to an increase in optimal age to between 334 and 428 months
for three serotypes and 219 months for four serotypes. Similar results are
obtained for age-dependent efficacy where the optimal vaccination ages for
risk-free primary infections are 109 months for all combinations apart from
DENv1, 2 and 3, which requires vaccination at 278 months. For risk-free
primary infections the ages again increase to between 319 and 417 months
for three and to 215 months for four serotypes. So the current vaccination
guidelines are reasonable if vaccination aims to limit the risk of death due
to Dengue and secondary infections are the main cause for serious cases of
Dengue independently of whether efficacy is age-dependent or not.
7. Discussion
In this paper we have studied a mathematical model to find the opti-
mal vaccination age for Dengue vaccination in Brazil. We used data from
the Brazilian Health Ministry to calculate R0 for each of the four Dengue
serotypes and then adapted the method of Hethcote [1] to find the optimal
vaccination age. The vaccine has differing efficacies for each serotype. We
started off with the situation where there was just one serotype in circulation
and then moved on to the optimal vaccination ages for multiple serotypes.
The optimal vaccination ages were found for both constant vaccine effective-
ness across all ages and when the vaccine efficacy depends on the age at which
each dose is given. For the case where multiple serotypes were present the
calculations were done first for the first infection being risky and secondly
for only subsequent infections being risky (to model Dengue Antibody En-
hancement). Note that the model is intended to estimate the optimal age to
vaccinate in the routine vaccination calendar. No catch-up campaigns were
considered.
As one commonly accepted theory is that any Dengue infections after
the second one do not cause serious effects due possibly to partial immunity
the calculations were then repeated excluding these infections. All of these
calculations were done twice, first with the risk function being hospitalisation
and secondly when it is mortality. The assumption that a second infection
with Dengue is more risky than a first infection is commonly made. One
theory is that a first infection provides some immunity, but that if immunity
fails resulting in a secondary infection, the risk is higher. Burattini et al.
[47] claim that hospitalisation risk is almost the same for those who have
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or have not had a recorded secondary infection. This does not necessarily
contradict a second infection being more risky as primary infections are often
asymptomatic.
On the other hand there seems substantial evidence in the literature that
vaccination with Dengvaxia increases hospitalisation risk on Dengue infection
relative to seronegative individuals [28], particularly for children. For the
Dengvaxia trials, in Asian sites in year three, the Dengue hospitalisation
rate was significantly higher among vaccinated children aged less than or
equal to five years of age (20 of 2,029 [0.99%]) than among controls (2 of
1,005 [0.2%]) with a relative risk of 4.95 (p = 0.3) [30, 50]. This is discussed
further by Halstead [26]. Moreover during year three of the Dengvaxia trials
there was an overall efficacy against hospitalisation of 16.7% but a relative
risk of hospitalisation of 1.6 amongst children younger than nine years of age
[30]. Halstead [27] discusses possible ways to improve the trial design and to
estimate vaccine efficacy taking into account that vaccination of seronegatives
increases their risk on subsequent infection.
It was found that for some serotype combinations the optimal age at
vaccination lay outside the range for which Dengvaxia is currently licensed,
whenever this was the case the resulting minimal lifetime expected risk was
compared with that found for ages between 9 and 45 years, a summary of
which is shown in Table 6. Tables 4 and 5 give an overview of the achieved
minimal lifetime expected risk with the corresponding optimal vaccination
ages for the risk of hospitalisation and death respectively. The optimal vac-
cination age to reduce the risk of hospitalisation was commonly found to be
below 9 years for constant efficacy especially when primary infections were
considered risky. For efficacy based on age-groups the optimal vaccination
age was always found to be within the range of the license. When consider-
ing lethality the results were often above 45 years, but for constant efficacy
there were also cases with optimal ages below 9 years. The much higher
vaccination ages found for the risk of death in comparison to those for hospi-
talisation are due to the high increase in risk at old compared to young ages.
The maximum risk for children is approximately 0.18 at 6 years for hospital-
isation and 0.0011 at 5 years for lethality, while for 75 year-olds the risk of
hospitalisation is only 0.14 and that of death is 0.0047, more than four times
the maximum risk for children. It is therefore essential for the vaccination
programme not to increase the average age of infections to high values in the
case of the risk being death which can be avoided by vaccinating after the
current average age of infection.
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All scenarios that required optimal vaccination at ages below 9 or above
45 years were investigated further by limiting the vaccination to start between
108 and 539 months. The optimal vaccination ages under these restrictions
were always found to decrease to 538 or 539 months in cases that required
vaccination above this age to achieve the minimal lifetime expected risk.
If vaccination was found to be optimal below 9 years the restrictions led to
optimal ages of 108 or 109 months for hospitalisation, for lethality there were
some cases where the age increased to above 500 months. The effect of the
age restriction on the lifetime expected risk varied significantly for all cases
with increases from the minimum value between 0.002% and almost 200%
(Table 6). For serotypes DENv3 and 4 separately as well as combined the
risk both of hospitalisation and lethality could be reduced to zero at young
ages, which was no longer the case under the age-restriction. The increase
was generally higher for hospitalisation.
In our simulations we used the risk of hospitalisation and death as substi-
tutes for the more severe reactions to Dengue such as DHF and DSS which
are considered most probable in secondary infections [51]. In almost all cases
the optimal vaccination age was higher for risk-free primary infections than
for the corresponding simulations with risky ones. This is to be expected
since vaccination is unnecessary prior to a primary infection if this infection
carries no risk for the infected. The exceptions to this led to very young
ages in either case. Further the efficacy study by Hadinegoro et al. [30] im-
plies that the assumption of a constant efficacy may be an oversimplification
so that an age-dependent efficacy reflects the actual conditions more accu-
rately. Our simulations showed that in most cases the optimal vaccination
age is significantly higher if the efficacy is based on age-groups rather than
constant. This is because the efficacy found for vaccination at age 9 or above
is much higher for each serotype than if vaccines are administered to younger
children so that in most cases simulated optimal vaccination could only be
achieved with this higher efficacy. Taking these more realistic scenarios of
age-dependent efficacy and risk-free primary infections every optimal vacci-
nation age for the hospitalisation risk was within 9-45 years. The reduction
of the risk of death was found to be optimal for vaccination ages that in
some cases were above 45 years. However, the optimal vaccination ages var-
ied significantly for the number of co-circulating serotypes as well as for the
specific serotype combinations. The lowest optimal vaccination age for age-
dependent efficacy was found to be 108 months; this was found for several
scenarios, e.g. for the only serotype in circulation being DENv4 and with
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the risk being mortality. The highest age found with efficacy based on age-
groups was 728 months which was found to minimise the risk of death for
a combination of DENv1 and DENv2 when a primary infection was free of
risk.
We also considered third and fourth infections to be asymptomatic as this
is a common theory and have found that in many of the scenarios there is
little difference in the optimal vaccination age in comparison to symptomatic
tertiary and quaternary infections for hospitalisation risk. However if lethal-
ity is considered asymptomaticity resulted in optimal vaccination ages that
were within the age range of 9-45 years for almost all serotype combinations.
Our results therefore demonstrate that we must think about the main
objective of the vaccine as well as the serotypes which are in circulation in a
region where Dengue is endemic before specific vaccination campaigns can be
considered. It is probable that the higher efficacy of Dengvaxia in individuals
older than 9 years is more dependent on the occurrence of previous infections
than on the increasing age per se ([25, 26, 28, 52]). This would mean that
the vaccine efficacy is poor and a little better only in the case of previous
Dengue infection. If this is true then the assumptions of equal efficacy within
all age classes are the most accurate ones. Especially serotype combinations
including DENv2 resulted in higher lifetime expected risk so that the exact
efficacy is important. Moreover the results presented were obtained for a
constant death rate µH which is widely accepted in epidemiological modelling
as an approximation but does not adequately describe population dynamics
in developed countries so that the optimal vaccination ages are indications
only.
Additionally one could easily use our methods to propose optimal vaccina-
tion strategies other than the ones for which Dengvaxia is currently licensed.
For example the first vaccination could be given at early ages and then a
booster dose at older ages.
Note that this work differs from previous work in that we have included
the survival probability in the risk function. We believe that this gives a bi-
ologically more accurate risk function. Note also that the work assumes that
the spread of different Dengue serotypes are independent. It is commonly
believed that infection with one serotype provides permanent immunity to
that serotype but temporary immunity to other serotypes. It would be most
accurate to model this explicitly but as the period of cross-protection is rel-
atively short the current model may provide a realistic approximation. As
Dengvaxia is currently undergoing Phase IV trials Dengue vaccination and
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the appropriate age at which to do it is a real practical problem and deter-
mination of the effects of different vaccination programs is vital and urgently
needed.
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